Cosmo achieves robust financial performance in H1 2024 and confirms its full year guidance

Dublin, Ireland – 24 July 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced its 2024 half year results.

Giovanni Di Napoli, CEO of Cosmo, commented: “We are delighted to report a robust financial performance for the first half of 2024, with revenues reaching €136.2 million, operating profits at €87.0 million, and operating cash flows of €99.2 million. Our flagship products, GI Genius™ and Winlevi®, are driving significant revenue growth, while our pipeline of innovative new products is poised to tap into large, high-potential markets. These outstanding results underscore our commitment to quality, innovation, and enhancing healthcare outcomes for patients worldwide.”

Revenue in the first half of 2024 increased to €136.2 million compared to €43.7m in the same period last year. Health Tech revenue increased to €97.5 million compared to €6.4 million last year; the increase was driven by the receipt of an upfront payment from Medtronic related to the expansion of the AI partnership. Dermatology revenue increased by 58.5% to €7.4 million due to increases in net sales and the continued global expansion of Winlevi ^® . Gastroenterology royalty and supply revenue increased by 4.3% to €21.4 million. CDMO revenue increased by 9.3% to €8.9 million driven by an increase in orders from existing customers.

Net expenses in the first half were €49.2 million compared to €36.5 million in the same period last year. Expenses related to raw materials and consumables increased to €9.2 million compared to €8.6 million in the same period last year as a result of an increase in product shipments in the first half. Personnel expenses increased to €19.9 million compared to €12.2 million last year; the rise in expenses is attributed to an expanded R&D headcount, additional personnel costs related to higher production activity, and higher short-term incentive payments linked to the financial performance Outsourced preclinical and clinical trials costs increased to €2.3 million (H1 2023: €1.5 million) linked to the initiation of the Distal Ulcerative Colitis phase II proof-of-concept study and the costs associated with the preparation for the Bile Acid Diarrhoea phase II proof-of-concept study. Other operating expenses increased by €3.1 million to €10.8 million manly due to an increase in contingent consideration provisions linked to the Company’s new agreement with Medtronic and an increase in production related costs. Depreciation and amortisation increased by €0.4 million to €7.3 million.

Net financial income was €1.8 million compared to net financial expenses of €3.5 million in H1 2023; the gain relates to interest income on Cosmo’s cash balances and gains on the sale of short-term bond investments. The net financial expenses last year include imputed convertible bonds which were redeemed in the last quarter of 2023 and therefore no change arises in the reporting period.

Profit before tax was €88.7 million (H1 2023: €3.7 million) and profit after tax was €76.1 (H1 2023: €1.5 million).

EUR 1’000	H1 2024	H1 2023
Income statement
Revenue	136,237	43,661
Cost of sales	(23,150)	(18,871)
Gross profit	113,087	24,790
Other income	1,014	425
R&D costs	(10,824)	(8,288)
SG&A costs	(16,323)	(9,804)
Net operating expenses	(26,133)	(17,667)
Operating profit	86,954	7,123
Net financial income/(expenses)	1,794	(3,450)
Profit before taxes	88,748	3,673
Profit after taxes for the period	76,058	1,486

Statement of financial position	30 Jun 2024	31 Dec 2023
Non-current assets	454,658	451,754
Cash and cash equivalents	54,556	50,275
Other current assets	129,038	51,951
Liabilities	132,866	124,944
Equity attributable to owners of the Company	498,443	422,160
Non-controlling interests	6,943	6,876
Equity ratio (%)	79.2%	77.4%

Shares	H1 2024	H1 2023
Weighted average number of shares	16,105,126	16,146,054
Earnings per share (in EUR)	4.718	0.092

Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast presentation with Giovanni Di Napoli, CEO, and Niall Donnelly, CFO, to discuss the financial and operating results as well as the next milestones of the Company:

Cosmo is a pharmaceutical company focused on developing and commercializing products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions, and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally by selected partners including Lialda® /Mezavant®/Mesavancol®, Uceris®/Cortiment®, Aemcolo®/ Relafalk®, Lumeblue® and Winlevi®. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ which uses artificial intelligence to help detect potential signs of colon cancer. The company also has a rich development pipeline. For additional information on Cosmo and its products please visit the Company’s website: www.cosmopharma.com .

Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.

EUR 1,000	Half Year
	2024	2023
Revenue	136,237	43,661
Net expenses	(49,283)	(36,538)
Operating profit	86,954	7,123
Net financial income	1,794	(3,450)
Profit before taxes	88,748	3,673
Income tax	(12,690)	(2,187)
Profit after taxes	76,058	1,486
Basic EPS	4.718	0.092
Basic weighted average number of shares	16,105,126	16,146,054
Diluted EPS	4.705	0.092
Diluted weighted average number of shares	16,150,246	16,146,054

Attachments